Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Ana Parra, Claudia Hernández & Laura Prieto-Pinto. (2023) Evaluation of the economic benefits, administration times, and patient preferences associated with the use of biotechnological drugs administered subcutaneously and intravenously in patients with cancer: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 0:0, pages 1-10.
Read now
Read now
Advait V Badkar, Rajesh B Gandhi, Shawn P Davis & Michael J LaBarre. (2021) Subcutaneous Delivery of High-Dose/Volume Biologics: Current Status and Prospect for Future Advancements. Drug Design, Development and Therapy 15, pages 159-170.
Read now
Read now
Mattia Altini, Nicola Gentili, William Balzi, Gerado Musuraca, Roberta Maltoni, Carla Masini, Francesca Galardi, Lucia Bertoni & Ilaria Massa. (2021) The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology. Expert Review of Pharmacoeconomics & Outcomes Research 21:3, pages 503-509.
Read now
Read now
Yohei Ozawa, Kristin C. Hicks, Christine M. Minnar, Karin M. Knudson, Jeffrey Schlom & Sofia R. Gameiro. (2021) Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa. OncoImmunology 10:1.
Read now
Read now
András Inotai, Tamás Ágh, Alexei Willem Karpenko, Antal Zemplényi & Zoltán Kaló. (2019) Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries. Expert Review of Pharmacoeconomics & Outcomes Research 19:2, pages 105-113.
Read now
Read now
Articles from other publishers (5)
A. M. Alonso Torres, A. G. Arévalo Bernabé, N. Becerril Ríos, M. F. Hellín Gil, J. M. Martínez Sesmero, V. Meca Lallana, Ll. Ramió-Torrentà, A. Rodríguez-Antigüedad, L. Gómez Maldonado, I. Triana Junco, M. Gómez-Barrera, N. Espinoza Cámac & I. Oyagüez. (2023) Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain. PharmacoEconomics - Open 7:3, pages 431-441.
Crossref
Crossref
Sahar Awwad & Ukrit Angkawinitwong. (2018) Overview of Antibody Drug Delivery. Pharmaceutics 10:3, pages 83.
Crossref
Crossref
G. Lopez-Vivanco, J. Salvador, R. Diez, D. López, M. De Salas-Cansado, B. Navarro & J. De la Haba-Rodríguez. (2017) Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain. Clinical and Translational Oncology 19:12, pages 1454-1461.
Crossref
Crossref
Alberto Farolfi, Paolo Silimbani, Davide Gallegati, Elisabetta Petracci, Alessio Schirone, Mattia Altini & Carla Masini. (2017) Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients. Oncotarget 8:46, pages 81343-81349.
Crossref
Crossref
Sofia Maximiano, Paulo Magalhães, Mara Pereira Guerreiro & Manuel Morgado. (2016) Trastuzumab in the Treatment of Breast Cancer. BioDrugs 30:2, pages 75-86.
Crossref
Crossref